An individual theme involving the exclusive out-licensing of the anti-α9 integrin antibody GND-001 to Kaken Pharmaceutical, with the company supporting development of a large-scale manufacturing process, narrowing the target indications and global expansion in return for milestone payments and royalties, followed by termination of the license agreement.